Journal
NATURE REVIEWS CANCER
Volume 10, Issue 1, Pages 23-36Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc2765
Keywords
-
Categories
Funding
- US National Institutes of Health [CA127277, CA118319]
- G. Harold and Leila Y. Mathers Charitable Foundation
- Leukaemia & Lymphoma Society Translational Research Grant
- Spastic Paralysis Foundation of the Illinois, Eastern Iowa Branch of Kiwanis International
- American Society of Clinical Oncology Career Development Award
- American Cancer Society Institutional Grant
- NATIONAL CANCER INSTITUTE [R01CA127277, R01CA118319] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Acute leukaemias are characterized by recurring chromosomal aberrations and gene mutations that are crucial to disease pathogenesis. It is now evident that epigenetic modifications, including DNA methylation and histone modifications, substantially contribute to the phenotype of leukaemia cells. An additional layer of epigenetic complexity is the pathogenetic role of microRNAs in leukaemias, and their key role in the transcriptional regulation of tumour suppressor genes and oncogenes. The genetic heterogeneity of acute leukaemias poses therapeutic challenges, but pharmacological agents that target components of the epigenetic machinery are promising as a component of the therapeutic arsenal for this group of diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
